Qionghong Y. Xie

12 Middle Wulumuqi Road
Shanghai, 200040, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 47 publications

Staged soft tissue augmentation in multidisciplinary treatment of stage Ⅲ periodontitis: an 8-year follow-up case report

Staged soft tissue augmentation in multidisciplinary treatment of stage Ⅲ periodontitis: an 8-year follow-up case report

Journal: Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology
Published: March 31, 2026

Characteristics of adult membranous nephropathy patients with capillary co-deposition of IgG and IgA.

Characteristics of adult membranous nephropathy patients with capillary co-deposition of IgG and IgA.

Journal: Renal failure
Published: June 25, 2025

Reexamining the Causal Link Between Immunosuppression Delay and Kidney Outcomes in Autoimmune Membranous Nephropathy.

Reexamining the Causal Link Between Immunosuppression Delay and Kidney Outcomes in Autoimmune Membranous Nephropathy.

Journal: Kidney international reports
Published: June 03, 2025

Changes in the spectrum of biopsy-proven renal diseases over 11 years: a single-center study in China.

Changes in the spectrum of biopsy-proven renal diseases over 11 years: a single-center study in China.

Journal: Renal failure
Published: July 23, 2024

Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy.

Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: June 19, 2024

Relapse Risk in Patients with Membranous Nephropathy after Inactivated COVID-19 Vaccination.

Relapse Risk in Patients with Membranous Nephropathy after Inactivated COVID-19 Vaccination.

Journal: Nephron
Published: April 23, 2024

Obinutuzumab treatment for membranous nephropathy: effectiveness and safety concerns during the COVID-19 pandemic.

Obinutuzumab treatment for membranous nephropathy: effectiveness and safety concerns during the COVID-19 pandemic.

Journal: Clinical kidney journal
Published: April 10, 2024

Case report: BTK inhibitors is effective in type II mixed cryoglobulinemia with wild-type MyD88.

Case report: BTK inhibitors is effective in type II mixed cryoglobulinemia with wild-type MyD88.

Journal: Frontiers in immunology
Published: February 27, 2024

Retroperitoneal leakage as an important cause of acquired ultrafiltration decline in peritoneal dialysis: clinical characteristics and related risk factors.

Retroperitoneal leakage as an important cause of acquired ultrafiltration decline in peritoneal dialysis: clinical characteristics and related risk factors.

Journal: Journal of nephrology
Published: December 07, 2023

Aggressive treatment may be needed for idiopathic membranous nephropathy with focal segmental glomerulosclerosis lesions.

Aggressive treatment may be needed for idiopathic membranous nephropathy with focal segmental glomerulosclerosis lesions.

Journal: Revista da Associacao Medica Brasileira (1992)
Published: November 23, 2023

Target Antigens of Membranous Nephropathy With Syphilis Infection.

Target Antigens of Membranous Nephropathy With Syphilis Infection.

Journal: Kidney international reports
Published: July 23, 2023

Knockout of the C3a receptor protects against renal ischemia reperfusion injury by reduction of NETs formation.

Knockout of the C3a receptor protects against renal ischemia reperfusion injury by reduction of NETs formation.

Journal: Cellular and molecular life sciences : CMLS
Published: April 26, 2023
Showing 1-12 of 47

Last Updated: 09/26/2026